Track Gossamer Bio, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Gossamer Bio, Inc. GOSS · Stock Open Gossamer Bio, Inc. in new tab

10.97 USD
EPS
-41.48
P/B
-0.26
ROE
-783.37
Beta
2.27
Target Price
83.40 USD
Gossamer Bio, Inc. logo

Gossamer Bio, Inc.

🧾 Earnings Recap – Q1 2026

Gossamer Bio’s shares plunged 43.3% as investors reacted negatively to a cautious outlook marked by clinical signaling below the stringent prespecified statistical threshold and broad uncertainty on commercial viability, prompting a significant operational downsizing and cost containment.

  • The Phase III PROSERA study showed a modest 13.3 meter placebo-adjusted improvement in 6-minute walk distance with a p-value of 0.032, missing the stricter prespecified 0.025 alpha threshold for primary endpoint significance.
  • All four key secondary endpoints favored seralutinib, but overall data leave ambiguity on clinical meaningfulness for regulatory approval.
  • The company is pursuing an NDA submission in September 2026 based on PROSERA plus earlier TORREY data, but the timing and success remain contingent on the upcoming Type B pre-NDA FDA meeting.
  • Operationally, the company announced a drastic workforce reduction (~50%) and paused other development programs to preserve capital amid uncertainty.
  • Engagement with convertible noteholders aims to manage looming 2027 maturities, reflecting financial caution as the PROSERA results introduce significant risk to near-term commercial prospects.
📅
Loading chart...
Key Metrics
Earnings dateMarch 12, 2027
EPS-41.48
Book Value-42.03
Price to Book-0.26
Debt/Equity376.14
% Insiders1.666%
Growth
Revenue Growth1.89%
Estimates
Forward P/E-1.06
Forward EPS-10.32
Target Mean Price83.40

DCF valuation

Model fair value for Gossamer Bio, Inc. (GOSS)
Result
Sign in to run the valuation for GOSS.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
6 analysts · consensus Buy · mean target 83.40 USD (low 22.40, high 160.00) · as of 16 Nov 2026
Low 22.40
Mean 83.40
High 160.00
Price 10.97
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Gossamer Bio, Inc. Logo Gossamer Bio, Inc. Analysis (GOSS)

United States Health Care Official Website Stock

Is Gossamer Bio, Inc. a good investment? Gossamer Bio, Inc. (GOSS) is currently trading at 10.97 USD. Market analysts have a consensus price target of 83.40 USD. This suggests a potential upside from current levels.

Earnings Schedule: Gossamer Bio, Inc. is expected to release its next earnings report on March 12, 2027. The market consensus estimate for Forward EPS is -10.32.

Investor FAQ

Does Gossamer Bio, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Gossamer Bio, Inc.?

Gossamer Bio, Inc. is classified as a Stock. You can compare it against 3 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be March 12, 2027. The company currently has a trailing EPS of -41.48.

Company Profile

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.

Exchange Ticker
FRA (Germany) 4GB.F
MUN (Germany) 4GB.MU
NMS (United States) GOSS
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
Sept. 11, 2026 1:80
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion